What is the difference between Ovagen and Svetinorm?

Both target liver tissue, but Ovagen is a synthetic single tripeptide (Glu-Asp-Leu), while Svetinorm is a natural peptide complex extracted from animal liver tissue. Svetinorm contains a broader mix of peptides; Ovagen is the simplified, synthetic counterpart in Khavinson's Cytogen/Cytomax system.

Is there PubMed evidence for Ovagen?

There are no PubMed-indexed studies specifically on Ovagen or the EDL tripeptide. The theoretical basis comes from broader Khavinson research on short peptides penetrating cell nuclei and regulating gene expression, which has been demonstrated for other peptides in the system.

Is Ovagen FDA-approved?

No. Ovagen is not FDA-approved and is not used in mainstream Western medicine. It is part of the Khavinson bioregulator system used primarily in Russian clinical settings.

Ovagen

A synthetic tripeptide bioregulator (Glu-Asp-Leu) from the Khavinson system, studied for liver tissue support, hepatoprotection, and gastrointestinal health.

LimitedLimited Data

What is Ovagen?

Ovagen is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu, or EDL), developed as part of Vladimir Khavinson's bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in liver tissue. Its natural-extract counterpart is Svetinorm. Like other Khavinson bioregulators, Ovagen is proposed to penetrate cell nuclei and modulate gene expression in a tissue-specific manner, targeting hepatocytes and gastrointestinal cells.

Why People Talk About It

Liver tissue support and hepatoprotection

Limited

GI mucosal protection

Limited

Liver fibrosis mitigation

Limited

Antioxidant defense in hepatocytes

Limited

How It Works

Ovagen is a small three-amino-acid peptide proposed to enter liver cells and reach the nucleus, where it may influence which genes are active. The goal is to support the liver's natural repair and detoxification processes, particularly as these functions decline with age.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated per Khavinson bioregulator program reportsMild digestive changes possible (oral form)

Cautions

• Not FDA-approved
• No PubMed-indexed safety or efficacy data specific to Ovagen
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

No Western or PubMed-indexed clinical trial data exists for Ovagen specifically. Safety claims are extrapolated from the broader Khavinson bioregulator program. Long-term effects are unknown.

Published Research

4 studies

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

Mechanism of Action

Ovagen (Glu-Asp-Leu) is proposed to penetrate hepatocyte membranes via POT family peptide transporters (PEPT1, PEPT2) and interact directly with DNA and histone proteins in the nucleus. Based on the broader Khavinson short-peptide framework, it is theorized to bind AT-rich DNA sequences in regulatory regions of liver-specific genes, promoting chromatin decondensation and reactivating genes involved in protein synthesis, antioxidant defense, and hepatocellular repair. However, these specific molecular interactions have not been experimentally validated for the EDL sequence — the proposed mechanism is extrapolated from studies on other Khavinson bioregulators like Vesugen (KED) and Epithalon (AEDG).

Evidence Snapshot

Overall Confidence15%

Human Clinical Evidence

None indexed in PubMed. No human clinical trials specific to Ovagen or the EDL tripeptide have been published in peer-reviewed literature accessible through Western databases.

Animal / Preclinical

None indexed in PubMed for Ovagen specifically. The theoretical basis rests on broader Khavinson research demonstrating that short peptides (2-4 amino acids) can penetrate cell nuclei, bind DNA, and modulate gene expression in tissue-specific ways.

Mechanistic Rationale

Weak for Ovagen specifically; moderate for the broader peptide class. The Khavinson framework of short peptide bioregulation has published evidence for related peptides (Vesugen, Pancragen, Epithalon), but the EDL sequence lacks independent mechanistic studies.

Forms & Administration

Ovagen is available in capsule and sublingual formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Liver tissue support and hepatoprotection

Limited15%

GI mucosal protection

Limited15%

Liver fibrosis mitigation

Limited15%

Antioxidant defense in hepatocytes

Limited15%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated per Khavinson bioregulator program reportsMild digestive changes possible (oral form)

Cautions

• Not FDA-approved
• No PubMed-indexed safety or efficacy data specific to Ovagen
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

No Western or PubMed-indexed clinical trial data exists for Ovagen specifically. Safety claims are extrapolated from the broader Khavinson bioregulator program. Long-term effects are unknown.

Published Research

4 studies

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

All references link directly to PubMed. Citations are selected by clinicians for relevance and quality.

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Vesugen

Preliminary

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

Vesilute

Preliminary

A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.

Pancragen

Preliminary

A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp) from the Khavinson system, studied for pancreatic function, glucose metabolism, and age-related type 2 diabetes.

Larazotide

ModerateBeginner

A synthetic peptide that regulates intestinal tight junctions, in clinical trials for celiac disease and studied for leaky gut conditions.

Quick Facts

Class: Bioregulator Peptide
Evidence: Limited
Safety: Limited Data
Updated: Apr 2026
Citations: 4PubMed

Also known as

Glu-Asp-LeuEDL TripeptideLiver Bioregulator

Evidence Score

Overall Confidence15%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.